Larry G. Edwards
Chief Executive Officer at Aicuris Anti-Infective Cures AG
Larry G. Edwards active positions
Companies | Position | Start | End |
---|---|---|---|
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Director/Board Member | - | - |
Independent Dir/Board Member | 2021-01-04 | - | |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Director/Board Member | 2021-02-28 | - |
La Jolla Pharmaceutical II BV
La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Director/Board Member | - | - |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Chief Executive Officer | 2023-03-31 | - |
Career history of Larry G. Edwards
Former positions of Larry G. Edwards
Companies | Position | Start | End |
---|---|---|---|
LA JOLLA PHARMACEUTICAL COMPANY | Director/Board Member | 2020-10-28 | 2022-08-21 |
Chief Executive Officer | 2020-07-27 | 2023-03-31 | |
President | 2020-07-27 | 2023-03-31 | |
La Jolla Pharma LLC
La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Chief Executive Officer | - | 2023-03-31 |
President | - | 2023-03-31 | |
TETRAPHASE PHARMACEUTICALS, INC. | Director/Board Member | 2019-07-31 | 2020-07-27 |
Chief Executive Officer | 2019-07-31 | 2020-07-27 | |
Chief Operating Officer | 2018-02-28 | 2019-06-30 | |
Corporate Officer/Principal | 2015-12-31 | 2018-02-28 | |
President | 2019-07-31 | 2020-07-27 | |
Sales & Marketing | 2015-06-30 | 2015-12-31 | |
CUBIST PHARMACEUTICALS INC | Sales & Marketing | 2014-03-31 | 2015-06-30 |
MERCK & CO., INC. | Corporate Officer/Principal | 2006-12-31 | 2009-12-31 |
Sales & Marketing | 2009-12-31 | 2013-12-31 | |
░░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ | - | - |
Training of Larry G. Edwards
Boston University | Masters Business Admin |
The Ohio University | Undergraduate Degree |
Statistics
International
United States | 9 |
Netherlands | 2 |
United Kingdom | 2 |
Operational
Director/Board Member | 5 |
Chief Executive Officer | 5 |
President | 4 |
Sectoral
Health Technology | 9 |
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Private companies | 9 |
---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
La Jolla Pharmaceutical II BV
La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Health Services |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
La Jolla Pharma LLC
La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Health Technology |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Health Technology |
Tetraphase Pharmaceuticals Ireland Ltd.
Tetraphase Pharmaceuticals Ireland Ltd. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals Ireland Ltd. is an Irish private company located in Dublin that manufactures basic pharmaceutical products. | Health Technology |
- Stock Market
- Insiders
- Larry G. Edwards
- Experience